Cara Therapeutics Inc (NASDAQ: CARA) open the trading on Wednesday, with great promise as it jumped 6.98% to $0.31, before settling in for the price of $0.29 at the close. Taking a more long-term approach, CARA posted a 52-week range of $0.24-$1.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 115.17%. Meanwhile, its Annual Earning per share during the time was -1.20%. This publicly-traded company’s shares outstanding now amounts to $54.48 million, simultaneously with a float of $45.76 million. The organization now has a market capitalization sitting at $17.07 million. At the time of writing, stock’s 50-day Moving Average stood at $0.2870, while the 200-day Moving Average is $0.5238.
Cara Therapeutics Inc (CARA) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Cara Therapeutics Inc’s current insider ownership accounts for 16.57%, in contrast to 32.18% institutional ownership. According to the most recent insider trade that took place on Nov 04 ’24, this organization’s PRESIDENT AND CEO sold 3,668 shares at the rate of 0.29, making the entire transaction reach 1,064 in total value, affecting insider ownership by 168,768. Preceding that transaction, on Aug 01 ’24, Company’s PRESIDENT AND CEO sold 4,149 for 0.35, making the whole transaction’s value amount to 1,452. This particular insider is now the holder of 172,436 in total.
Cara Therapeutics Inc (NASDAQ: CARA) Trading Performance Indicators
Let’s observe the current performance indicators for Cara Therapeutics Inc (CARA). It’s Quick Ratio in the last reported quarter now stands at 4.48. The Stock has managed to achieve an average true range (ATR) of 0.02. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.55.
In the same vein, CARA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.04, a figure that is expected to reach -0.38 in the next quarter.
Technical Analysis of Cara Therapeutics Inc (CARA)
[Cara Therapeutics Inc, CARA] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 64.56% While, its Average True Range was 0.0250.
Raw Stochastic average of Cara Therapeutics Inc (CARA) in the period of the previous 100 days is set at 41.94%, which indicates a major fall in contrast to 76.39% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 62.58% that was lower than 101.46% volatility it exhibited in the past 100-days period.
